Traders should monitor upcoming Phase 3 data readouts for DURAVYU in mid-2026 as a key catalyst. While current financials are deteriorating due to R&D investment and lapping of prior revenue, the cash runway supports execution through 2027. A successful DURAVYU readout could validate the investment story despite near-term losses.
Price Chart
Executive Summary
EyePoint reported a significant year-over-year decline in revenue and increased losses for Q4 and full-year 2025, driven by the completion of deferred revenue recognition from its YUTIQ license agreement. However, the company highlighted strong clinical progress with its lead candidate DURAVYU, including ongoing Phase 3 trials in wet AMD and DME, and secured a $306 million cash runway into Q4 2027. The appointment of a new Chief Commercial Officer signals preparation for a potential 2026-2027 product launch.
Key Financial Metrics
Key Facts
- Q4 2025 revenue dropped to $0.62 million from $11.59 million in Q4 2024 (-94.6% YoY)
- Full-year 2025 revenue declined to $31.37 million from $43.27 million in 2024 (-27.5% YoY)
- Net loss widened to $67.6 million in Q4 2025 vs $41.4 million in Q4 2024
- Full-year net loss increased to $232.0 million in 2025 vs $130.9 million in 2024
- Cash, cash equivalents, and investments totaled $306 million as of December 31, 2025
- DURAVYU Phase 3 topline data in wet AMD expected beginning mid-2026
- First patient dosed in Phase 3 COMO and CAPRI trials for DME with data expected in second half of 2027
- Michael Campbell appointed Chief Commercial Officer to lead DURAVYU launch
Financial Impact
Revenue down $11.9M YoY; operating expenses up $85.7M YoY; net loss increased by $101.1M; cash balance decreased by $65M year-over-year
Risk Factors
- Clinical trial failure or delay for DURAVYU could severely impact valuation
- Continuing high R&D spend may pressure cash runway if milestones are delayed
- FDA regulatory hurdles or warning letter issues at Watertown facility could delay approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249208 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 7, 2026 19d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3700 (−88.86%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3700 (−91.29%) |
Aug 18, 2026 9w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3700 (−94.13%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3700 (−92.40%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3700 (−96.98%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3700 (−97.12%) |
Jun 22, 2026 18w ago | 8-K | $13.73 $14.11 | ▲ +2.77% | ▲ +3.22% | $0.3700 (−97.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers